Advertisement
Research ArticleArticle

Development of a Rat Plasma and Brain Extracellular Fluid Pharmacokinetic Model for Bupropion and Hydroxybupropion Based on Microdialysis Sampling, and Application to Predict Human Brain Concentrations

Thomas I.F.H. Cremers, Gunnar Flik, Joost H.A. Folgering, Hans Rollema and Robert E. Stratford Jr.
Drug Metabolism and Disposition May 2016, 44 (5) 624-633; DOI: https://doi.org/10.1124/dmd.115.068932

Abstract

Administration of bupropion [(±)-2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-one] and its preformed active metabolite, hydroxybupropion [(±)-1-(3-chlorophenyl)-2-[(1-hydroxy-2-methyl-2-propanyl)amino]-1-propanone], to rats with measurement of unbound concentrations by quantitative microdialysis sampling of plasma and brain extracellular fluid was used to develop a compartmental pharmacokinetics model to describe the blood–brain barrier transport of both substances. The population model revealed rapid equilibration of both entities across the blood–brain barrier, with resultant steady-state brain extracellular fluid/plasma unbound concentration ratio estimates of 1.9 and 1.7 for bupropion and hydroxybupropion, respectively, which is thus indicative of a net uptake asymmetry. An overshoot of the brain extracellular fluid/plasma unbound concentration ratio at early time points was observed with bupropion; this was modeled as a time-dependent uptake clearance of the drug across the blood–brain barrier. Translation of the model was used to predict bupropion and hydroxybupropion exposure in human brain extracellular fluid after twice-daily administration of 150 mg bupropion. Predicted concentrations indicate that preferential inhibition of the dopamine and norepinephrine transporters by the metabolite, with little to no contribution by bupropion, would be expected at this therapeutic dose. Therefore, these results extend nuclear imaging studies on dopamine transporter occupancy and suggest that inhibition of both transporters contributes significantly to bupropion’s therapeutic efficacy.

Introduction

Bupropion [(±)-2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-one] was originally introduced as an effective medication for the treatment of depression (Wellbutrin). Among antidepressants, its mechanism is considered atypical in that it has no effects on the serotonergic system; rather, its efficacy in depression has been attributed to its ability to increase dopaminergic and noradrenergic tone, presumably via blockade of the respective synaptic reuptake transporters: the dopamine reuptake transporter (DAT) and the norepinephrine reuptake transporter (NET) (Fava et al., 2005). After its approval for depression, bupropion was also marketed as a smoking cessation aid (Zyban). In addition to its effects on the DAT and NET, it has been suggested that bupropion’s efficacy in nicotine dependence may be associated with alteration of central nicotinic acetylcholine receptor function (Slemmer et al., 2000; Damaj et al., 2004).

Single and repeat administration of therapeutic doses of bupropion in humans indicate that bupropion represents a minor fraction of the total bupropion-related plasma exposure, with one of its metabolites, hydroxybupropion [(±)-1-(3-chlorophenyl)-2-[(1-hydroxy-2-methyl-2-propanyl)amino]-1-propanone], representing the predominant circulating entity (Ascher et al., 1995; Jefferson et al., 2005). The relative systemic exposure of this metabolite to bupropion in repeated dosing ranges from 5- to 15-fold (Johnston et al., 2001; Learned-Coughlin et al., 2003; Benowitz et al., 2013). Given this significant difference, it has been suggested that hydroxybupropion, which has similar inhibitory activity at the DAT, but is a more potent NET inhibitor than bupropion, contributes significantly to bupropion’s efficacy (Ascher et al., 1995; Bondarev et al., 2003; Damaj et al., 2004; Lukas et al., 2010). Moreover, the higher exposure to hydroxybupropion may also be contributing to the side effects and adverse events associated with bupropion therapy, particularly seizures observed at higher doses (Wooltorton, 2002).

Use of animal models, particularly mice and rats, to understand the complex pharmacology of bupropion is hampered by the very different disposition of bupropion in animals versus humans. In these rodent species, hydroxybupropion contributes approximately 10% to the total systemic and whole brain exposure observed (Suckow et al., 1986), which is in complete reversal to the already-noted relative exposures observed in humans. Thus, superimposed upon remaining uncertainty regarding bupropion pharmacodynamics, either directly via inhibition of transporter-mediated reuptake of dopamine and norepinephrine or by indirect effects on these two neurotransmitter systems (Cooper et al., 1994; Dong and Blier, 2001), or via effects on nicotinic acetylcholine receptors (Slemmer et al., 2000; Damaj et al., 2004), the different metabolic disposition in rodents complicates the ability to extrapolate to humans. Although application of brain imaging modalities, such as positron emission tomography (PET) and single photon emission computed tomography (SPECT), has received considerable attention (Meyer et al., 2002; Learned-Coughlin et al., 2003; Árgyelán et al., 2005), these approaches cannot distinguish the contributions of bupropion and hydroxybupropion to measured receptor occupancy.

Previous studies have shown that a translational pharmacokinetics (PK)/pharmacodynamics (PD) approach can be of great value to increase understanding of the pharmacology of central nervous system drugs, particularly those with multiple targets and/or with active metabolites. This approach describes plasma-to-brain transfer [blood–brain barrier (BBB) transport], using compartmental or physiologically based pharmacokinetic modeling in animals, with subsequent coupling of measured human systemic PK with the human brain disposition derived from weight-based allometric scaling of the corresponding animal parameters (de Lange, 2013). The method has been used to predict atomoxetine and duloxetine exposure in human brain extracellular fluid (ECF) (Kielbasa and Stratford, 2012), risperidone and its metabolite (9-OH-resperidone) receptor occupancy (Kozielska et al., 2012), olanzapine receptor occupancy (Johnson et al., 2011), and receptor occupancy of clozapine and its active metabolite (N-desmethylclozapine) at multiple receptors, based on brain ECF measures using microdialysis (Li et al., 2014). In these examples, predicted exposure and/or occupancy in the human brain after subtherapeutic or therapeutic doses was accordingly congruent with in vitro receptor potency (Kielbasa and Stratford, 2012) or with receptor occupancy measured by PET imaging (Johnson et al., 2011; Kozielska et al., 2012; Li et al., 2014). Thus, the objective of our study was to apply this translational approach to predict bupropion and hydroxybupropion exposure in human brain ECF, the pharmacologically relevant biophase for the purported parenchymal membrane targets. To this end, single doses of bupropion and its preformed metabolite were administered to two groups of rats, with subsequent application of population compartmental modeling of measured unbound concentrations from quantitative microdialysis sampling of both plasma and brain ECF. Structural parameters describing brain ECF disposition were then scaled to predict the time course of both entities in human brain ECF.

Materials and Methods

Drugs and Chemicals.

Bupropion (racemic) and (2S,3S)-hydroxybupropion hydrochloride were purchased from Sigma-Aldrich (St. Louis, MO) and were used as received. Formulations for administration were prepared on the day of an experiment. Chemicals used in the preparation of microdialysis perfusion buffer and solvents used for high-performance liquid chromatography (HPLC)–tandem mass spectrometry (MS/MS) analysis were of reagent grade.

Animal Preparation.

Adult male Sprague-Dawley rats (280–350 g; Harlan, Horst, The Netherlands) were used for the experiments. The experiments were conducted in strict accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals, were in accordance with Dutch law, and were approved by the Animal Care and Use Committee of the University of Groningen (Groningen, The Netherlands). After arrival, animals were housed in groups of five in polypropylene cages (40 × 50 × 20 cm) with a wire mesh top in a temperature-controlled (22 ± 2°C) and humidity-controlled (55% ± 15%) environment on a 12-hour light cycle (07.00–19.00). After surgery, animals were housed individually (cages 30 × 30 × 30 cm). Standard diet (Diets, RMH-B 2181; ABDiets, Woerden, The Netherlands) and domestic-quality mains water were available ad libitum.

Surgery for implantation of the microdialysis guide cannula was conducted under isoflurane anesthesia (2% with 400 ml/min N2O and 400 ml/min O2), using bupivacaine/epinephrine for local analgesia and finadyne for perioperative/postoperative analgesia. One guide cannula was inserted into the medial prefrontal cortex to achieve the following probe tip coordinates: anteroposterior, +3.4 mm from bregma; lateral, –0.8 mm from midline; and ventral, –5.0 mm from dura. A second 4.2-cm indwelling cannula was inserted into the jugular vein. Guide cannulae were exteriorized through an incision at the top of the head. Animals were allowed at least 2 days to recover from surgery. MetaQuant Ultra-Slow Flow microdialysis probes (regenerated cellulose membrane, 4-mm open membrane surface; BrainLink, Groningen, The Netherlands) were inserted 1 day before the experiments.

Drug Administration and Sample Collection.

On the day of an experiment, probes were connected with flexible PEEK tubing to a CMA 102 microdialysis pump (CMA Microdialysis, Solna, Sweden) and perfused with a filtered Ringer’s buffer containing 147 mM NaCl, 3.0 mM KCl, 1.2 mM CaCl2, and 1.2 mM MgCl2 at a flow rate of 0.12 µl/min (CMA 142 pump). The slow flow design of this probe maximizes sample recovery (Cremers et al., 2009), which was 91% for bupropion and 100% for hydroxybupropion, as determined from in vitro recovery experiments. Ultrapurified water was perfused through the dilution inlet of the probe at a flow rate of 0.8 µl/min; thus, the total dialysate flow rate was 0.92 µl/min. After initiating flow, probes were allowed to stabilize for 2 hours prior to administration of a single subcutaneous dose of bupropion (10 mg/kg, n = 7 with partial overlap for each matrix) or hydroxybupropion (2 mg/kg, n = 4), both dissolved in 0.9% NaCl at 2 mg/ml. Dialysates from the brain and jugular vein were collected every 30 minutes starting 1 hour prior to administration and continuing for 360 minutes after drug administration. Dialysate samples were stored at −80°C until time of analysis.

Sample Analysis.

Concentrations of compounds were measured in dialysate collected from plasma and brain ECF probes using HPLC with MS/MS detection. An aliquot of 12 μl was taken from each MetaQuant dialysate sample (27.6 μl total volume) and mixed with 4 μl internal standard solution (fenfluramine). Of this mixture, 10 μl was injected into the HPLC system by an automated sample injector (SIL-20AD; Shimadzu, Kyoto, Japan). Chromatographic separation of the compounds was performed on a reversed phase column (100 × 3.0 mm, 2.5 µm particle size; Phenomenex, Torrance, CA) held at a temperature of 35°C in a gradient elution run, using eluent B (acetonitrile) in eluent A (10 mM ammonium formate in ultrapurified water, pH 4) at a flow rate of 0.3 ml/min. The gradient profile was as follows: 0% B from 0 to 4 minutes, 40%–100% B from 4 to 5.5 minutes, remaining at 100% B until 6 minutes, and returning to 0% B from 6 to 6.5 minutes. The mass spectrometry analyses were performed using an API 4000 MS/MS system consisting of an API 4000 MS/MS detector and a Turbo Ion Spray interface (both from Applied Biosystems, Foster City, CA). The acquisitions were performed in positive ionization mode, with ionization spray voltage set at 5.5 kV and a probe temperature of 500°C. The instrument was operated in multiple reaction monitoring mode. Multiple reaction monitoring transitions were 239.9 to 183.9 for bupropion and 256.0 to 166.0 for hydroxybupropion. Suitable in-run calibration curves were fitted using weighted (1/x) regression, and the sample concentrations were determined using these calibration curves. Standard concentrations ranged from 0.05 to 50.0 nM. Accuracy was verified by quality-control samples after each sample series. Concentrations were calculated with the Analyst data system (Applied Biosystems).

Pharmacokinetic Analysis.

All pharmacokinetic analyses were conducted with Phoenix NLME 1.3 (Pharsight Corporation, Certara, L.P., Princeton, NJ). A population modeling approach was used for both bupropion and hydroxybupropion using first-order conditional estimation. Initial models in plasma were built for each compound based on their corresponding dose group (bupropion and preformed hydroxybupropion). Different model structures were evaluated for each dose group. These included one- and two-compartment disposition and zero-order versus first-order absorption, with the latter including with versus without a lag time. Model evaluation was based on the likelihood-ratio test, which uses the objective function value (OFV). The minimum OFV returned for a model is approximately equal to −2 × log likelihood (−2LL). Reduction of −2LL > 6.63 for the addition of one parameter was taken as a significant model improvement (P < 0.01) for nested models. The Akaike information criterion (AIC), which is calculated as AIC = −2LL + 2 × NP, where NP is the number of parameters, was used to compare models differing by more than one parameter. After optimization of the plasma model unique to each dose group, brain ECF concentrations were incorporated as a peripheral compartment. Transfer characteristics between the plasma and brain were modeled using either a single intercompartmental clearance (Q) or separate parameters for the uptake and efflux apparent distributional clearances (CLin and CLout, respectively). The unbound volume of distribution of bupropion in the brain (Vb,B) was tested with versus without fixing this parameter to a literature-reported value of 16 ml/g brain (Fridén et al., 2011). For hydroxybupropion, a computational approach was used to estimate its volume of distribution in the brain (Vb,HB) (Spreafico and Jacobson, 2013). Based on this approach, a value of 8 ml/g brain was used when this parameter was fixed. In addition to minimization of OFV, the combined plasma-brain ECF model selection also included stability of the plasma model–specific estimates upon incorporation of the brain ECF compartment.

In parallel with development of the plasma-brain models for each compound, a combined plasma model that incorporated hydroxybupropion concentrations observed after both bupropion administration (formed metabolite) and hydroxybupropion administration (preformed metabolite) was developed. Linkage of the two separate plasma models was made through the estimated parameter, bupropion-to-hydroxybupropion formation clearance (CLf). In addition to this postabsorptive conversion, presystemic metabolism of bupropion was evaluated. The final structural model combined this unified plasma model with the separate plasma-to-brain transfer models for the two compounds. In total, there were 11 rats and 367 observations in this final model. The possibility of within-brain metabolism was also investigated in this final model. At each model building stage, between-animal variability (BAV) was estimated for each pharmacokinetic parameter by assuming a log-normal distribution based on the exponential relationship, Pi = Ptv × exp(ηi), where Pi is the parameter estimate for the ith animal, Ptv is the population typical value, and ηi is the deviation from the population value for the ith subject. Various residual error models were also evaluated. These were additive, proportional, and mixed additive-proportional models. Residual error estimates of intra-animal variability between observed and predicted concentrations were assumed to be normally distributed with a variance of σ2. A proportional error model was eventually selected in the two matrices for both compounds.

Final plasma-specific and plasma-brain ECF models were evaluated based on visual inspection of conditional weighted residual versus either population predicted or time after dose plots as well as the observed versus individual predicted and population predicted concentration plots. A visual predictive check was also conducted, and parameter uncertainty was evaluated using a nonparametric bootstrap based on resampling 200 times from the original data set.

Human Exposure Simulations.

The final plasma-brain ECF model was scaled to predict steady-state human brain ECF exposure to bupropion and hydroxybupropion. A 150-mg dose of the extended-release (SR) bupropion product administered twice daily was selected based on studies of bupropion PK using this formulation and dose frequency (Johnston et al., 2001; Learned-Coughlin et al., 2003; Benowitz et al., 2013). Bupropion pharmacokinetic parameters used for the simulations were based on these studies and corrected for plasma protein binding of 85% (Jefferson et al., 2005). These were 17.5 l/min for CL/F and 12,400 liters for VD/F. An absorption rate constant (ka) of 0.01/min, which yielded a Tmax of 3 hours, the reported value for the SR formulation (Jefferson et al., 2005), was used. Pharmacokinetic parameters for formed hydroxybupropion were adjusted to provide an average unbound steady-state concentration of 500 nM. This concentration was between the reported average concentrations from the two multiple dose studies after correcting for hydroxybupropion plasma protein binding of 77% (Johnston et al., 2002). Both bupropion and hydroxybupropion pharmacokinetics are linear after long-term bupropion administration of 300–400 mg/d (Jefferson et al., 2005). Weight-based allometric scaling of the plasma-brain ECF distributional clearance (CL) and brain volumes was used to derive the corresponding human brain parameters, using a rat brain weight of 2.45 g (1.8 g/250 g body weight; Davies and Morris, 1993) and a human brain weight of 1.35 kg. The exponential factors were 0.75 for CL and 1.0 for brain distribution volume (Vb) (Sharma and McNeill, 2009). A total of 1000 simulations were conducted.

Data Presentation.

Rat plasma and brain ECF matrix concentration data are presented as unbound concentrations, and the corresponding time points are the midpoint of a given 30-minute collection interval. All pharmacokinetic parameters are presented as the unbound estimates.

Results

Subcutaneous administration of a 10-mg/kg dose of bupropion resulted in both parent drug and formed metabolite exposure in plasma and brain ECF (Table 1). The hydroxybupropion area under the curve (AUC0–∞) as a percentage of bupropion exposure was 6% ± 0.6% (n = 6) in plasma and 4% ± 0.3% in brain ECF (n = 6). The relative exposure in plasma agrees reasonably well with the 13% reported after a 40-mg/kg intraperitoneal dose to rats (Suckow et al., 1986). In addition, a recent microdialysis study (Yeniceli et al., 2011) measured comparable AUCs for bupropion (within 2-fold) and hydroxybupropion (within 3-fold) in brain ECF after a 10-mg/kg intraperitoneal dose to rats. In our study, for both plasma and brain matrices, a decline of the metabolite proceeded in parallel with that of bupropion; in addition, the terminal half-life in brain ECF was similar to the plasma for each compound (Table 1). With respect to preformed hydroxybupropion administration (2 mg/kg), its terminal half-life in both plasma and brain ECF was approximately 50% of its half-life observed after bupropion administration.

View this table:
TABLE 1

Bupropion and hydroxybupropion observational pharmacokinetic parameters in plasma and brain ECF after a subcutaneous 10-mg/kg dose of bupropion or a 2-mg/kg dose of hydroxybupropion by the same route

Results for AUC, Cmax, and AUCECF/AUCplasma,u ratio are presented as means (S.E.M.). Results for half-lives are presented as the geometric mean. There were a total of six rats in the bupropion administration group (five for plasma and five for brain), and four rats in the hydroxybupropion administration group.

The ratio of brain ECF concentration to unbound plasma concentration (Kp,uu) was on average above 1 at all times for bupropion and preformed hydroxybupropion (Fig. 1). AUC ratios, shown in Table 1, indicate a 2.1-fold asymmetry for bupropion and slightly lower values for both preformed and formed hydroxybupropion.

Fig. 1.
Fig. 1.

Bupropion and hydroxybupropion unbound concentration ratios of brain ECF to plasma (Kp,uu) in individual rats. The top panel presents bupropion ratios after a 10-mg/kg subcutaneous dose of bupropion, whereas the middle panel presents hydroxybupropion ratios observed in the same group of rats (formed metabolite case). The bottom panel presents hydroxybupropion ratios after a 2-mg/kg dose of the metabolite in a different group of rats by the same administration route (preformed metabolite case). The x-axis represents a given animal, with each point representing a sample time arranged in ascending order from left to right starting at 15 minutes and ending at 345 minutes in 30-minute increments. The solid horizontal line in each panel represents the plasma-to-brain equilibration model–predicted equilibrium Kp,uu value reported in Table 2.

Compartmental model structure definition for bupropion in plasma and brain ECF indicated that a one-compartment model provided the best description of concentration time course in both matrices, in agreement with visual inspection of monoexponential decline in individual animals (Fig. 2). The same was true for hydroxybupropion in both matrices, regardless of its disposition as formed or preformed metabolite. Estimation of bupropion and of preformed metabolite bioavailability resulted in population estimates > 95%. However, since precision of these estimates, as well as of the corresponding clearance and volume of distribution (VD) estimates was poor, bioavailability was fixed to 0.95 for bupropion to account for a small first-pass effect and to 1 for preformed hydroxybupropion. With respect to the description of plasma-to-brain ECF transfer, for bupropion and for its metabolite, estimation of CLin and CLout provided clearly superior results (minimization of OFV) relative to modeling this transfer as a single intercompartmental clearance. Importantly, an attempt was made to estimate the unbound brain volume of distribution for both bupropion (Vb,B) and hydroxybupropion (Vb,HB); however, it was necessary to fix this parameter for both compounds to get reliable estimates of the distributional clearances.

Fig. 2.
Fig. 2.

Compartmental pharmacokinetic model used to describe bupropion, and its formed and preformed metabolite absorption and disposition in rats. Terms with a subscript containing B represent bupropion, whereas those with HB, hydroxybupropion. CbECF,unbound brain ECF concentration; Cu,p, unbound plasma concentration; CL/F, apparent elimination clearance; CLf, apparent formation clearance of bupropion to hydroxybupropion; CLin, uptake apparent distributional clearance; CLout, efflux apparent distributional clearance; ka represents the first-order absorption rate constant; kf, first-order rate constant for presystemic conversion of bupropion to hydroxybupropion; Tlag, lag time for bupropion absorption; Vb, apparent brain volume of distribution; Vp, apparent systemic volume of distribution.

The initial approach to combine the plasma disposition of bupropion and hydroxybupropion after their subcutaneous administration was to fix the parameter estimates obtained from modeling the two administration groups separately to define the formation clearance for the formed hydroxybupropion. This approach led to a formation clearance of approximately 3.5 ml/min. Subsequent population modeling of plasma data simultaneously from both groups of animals, using this estimate and without fixing the parameters for the two compounds, resulted in model nonconvergence. Therefore, various plasma model structures were investigated. These included 1) the possibility that bupropion and hydroxybupropion had different bioavailability, 2) that bupropion was altering the clearance or VD of the formed metabolite, 3) a model that included a presystemic component to bupropion metabolism, and 4) a model that incorporated clearance of formed hydroxybupropion prior to it reaching the systemic circulation (the so-called “sequential first-pass elimination of the formed metabolite” model; Pang and Gillette, 1979). Neither different bioavailability nor the various clearance models could describe the observed alteration in formed metabolite disposition relative to the preformed metabolite. A model that invoked altered hydroxybupropion VD in the presence of bupropion was also unable to describe formed metabolite disposition. Ultimately, structure 3 above, a model that incorporated a presystemic (first-pass) component of bupropion conversion to hydroxybupropion, was selected as the final plasma model. Table 2 provides a summary of the final population model parameter estimates, as well as estimates of BAV for several of the parameters, and residual error. Also shown are the results of a nonparametric bootstrap to evaluate parameter stability in the plasma model. Figure 3 summarizes individual and population predicted concentrations versus the observed concentrations for both bupropion and hydroxybupropion in plasma, as well as the conditional weighted residuals distributions relative to both time and the population predicted concentrations.

View this table:
TABLE 2

Plasma bupropion and hydroxybupropion population pharmacokinetic parameter estimates

Data are given as percentages (percent relative standard error of the estimate) and medians (5th to 95th percentiles). BAV is calculated as the square root of the variance × 100.

Fig. 3.
Fig. 3.

Model diagnostic plots for plasma. (A and B) Individual predicted concentrations versus observed concentrations for bupropion and hydroxybupropion, respectively. The solid line is the line of unity. (C and D) Population predicted concentrations versus observed concentrations for bupropion and hydroxybupropion, respectively. (E and F) Conditional weighted residuals versus time for bupropion and hydroxybupropion, respectively. (G and H) Conditional weighted residuals versus population predicted concentrations for bupropion and hydroxybupropion, respectively. CWRES, conditional weighted residual; DV, concentration; IPRED, individual predicted; PRED, population predicted.

The final plasma-brain ECF model, which was based on fixed plasma parameter estimates with simultaneous analysis of brain ECF concentrations from both administration arms, is shown in Fig. 2. The assumption made in fixing the plasma estimates to derive the brain ECF estimates is that brain kinetics do not influence plasma kinetics. This assumption is supported by the much larger systemic volumes of distribution relative to those in the brain, as well as the two administration arm plasma-brain ECF–specific models that showed stability of the plasma estimates upon addition of the brain ECF component. The final model also incorporated a time-dependent component to CLin for bupropion (CLinb), expressed as CLinb = CLinb0 − slp × time, where CLinb decreases with time (slope) up to 195 minutes and is constant thereafter, and CLinb = CLinb0 when time = 0. A similar approach was recently used to describe time dependence in citalopram absorption in rats (Velez de Mendizabal et al., 2015) and was conceived in our case based on the observation in four of five rats of an overshoot in Kp,uu in the first half of the time course relative to the eventual Kp,uu,ss (Fig. 1). Table 3 provides a summary of population parameter estimates as well as estimates of BAV for the various plasma-to-brain ECF distributional clearances and proportional residual error.

View this table:
TABLE 3

Brain ECF bupropion and hydroxybupropion population pharmacokinetic parameter estimates

Data are given as percentages (percent relative standard error of the estimate) and medians (5th to 95th percentiles). BAV is calculated as the square root of the variance × 100.

Figure 4 summarizes individual and population predicted concentrations versus the observed concentrations for both bupropion and hydroxybupropion in brain ECF, as well as the conditional weighted residual distributions relative to both time and the brain ECF population predicted concentrations. Figure 5 summarizes the results of the visual predictive check for both compounds in plasma and brain ECF. Results from an evaluation of parameter precision in the final combined plasma and brain ECF model based on nonparametric bootstrap analysis are summarized in Table 3.

Fig. 4.
Fig. 4.

Model diagnostic plots for brain ECF. (A and B) Individual predicted concentrations versus observed concentrations for bupropion and hydroxybupropion, respectively. The solid line is the line of unity. (C and D) Population predicted concentrations versus observed concentrations for bupropion and hydroxybupropion, respectively. (E and F) Conditional weighted residuals versus time for bupropion and hydroxybupropion, respectively. (G and H) Conditional weighted residuals versus population predicted concentrations for bupropion and hydroxybupropion, respectively. DV, concentration; IPRED, individual predicted; PRED, population predicted; WRES, weighted residual.

Fig. 5.
Fig. 5.

Visual predictive checks for plasma (top) and brain ECF (bottom). The left plot in each panel represents bupropion after a 10-mg/kg dose bupropion, the middle plot represents formed hydroxybupropion after the 10-mg/kg bupropion dose, and the right plot in each panel represents preformed hydroxybupropion after a 2-mg/kg dose of the metabolite. The solid line in each plot represents the median of the observed concentrations, the dashed line represents the median predicted concentrations, and the two dotted lines represent the 5% and 95% limits of the predicted 90% confidence intervals of the median. Individual observed concentrations are shown as the open circles.

Figure 6 presents the predicted steady-state exposures in human plasma and brain ECF from 0 to 12 hours for bupropion and hydroxybupropion after twice-daily administration of the 150-mg extended-release bupropion SR tablet. The median maximum bupropion plasma concentration was 59 nM, occurring at 3 hours, which is the commonly observed peak time for the bupropion SR product (Jefferson et al., 2005), and the minimum concentration was 25 nM. These concentrations agree well with the reported maximum and minimum concentrations of 59 nM and 16 nM, respectively (Johnston et al., 2001), when corrected for bupropion’s plasma protein binding of 85% (Jefferson et al., 2005). Median predicted hydroxybupropion plasma concentrations varied little over the 12-hour time course (from 729 nM at the end of the dose interval to a peak of 798 nM 6 hours after administration) and agree well with reported steady-state hydroxybupropion plasma concentrations (Johnston et al., 2001; Learned-Coughlin et al., 2003) when corrected for hydroxybupropion’s plasma protein binding of 77% (Johnston et al., 2002). A comparison with reported IC50 values for DAT and NET (Damaj et al., 2004; Lukas et al., 2010) shows that unbound brain concentrations of hydroxybupropion after twice-daily administration of 150 mg bupropion SR exceed its IC50 values for DAT (630 nM) and NET (241 nM) over the entire time course, whereas bupropion concentrations were substantially lower than reported IC50s for the two transporters (660 nM and 1850 nM, respectively) at all times.

Fig. 6.
Fig. 6.

Simulated bupropion (left) and hydroxybupropion (right) concentrations over 12 hours in humans after multiple every-12-hour daily dosing of 150 mg of the bupropion SR formulation. The top panel represents plasma unbound concentrations, and the bottom panel represents brain ECF concentrations. The solid line describes the median predicted concentration, whereas the gray shaded lines represent the 5% and 95% predicted limits of the 90% confidence interval of the median concentrations. The dashed line in the brain ECF plots refers to the human IC50 value reported for the NET, and the dotted line refers to the IC50 for the DAT.

Discussion

Incorporation of a preformed hydroxybupropion administration group into the study design revealed that disposition of the formed metabolite was rate-limited by bupropion kinetics in both plasma and brain ECF. Coupled with the observation that preformed metabolite half-life in brain ECF was similar to that observed in plasma, these findings indicate that metabolite uptake and egress across the BBB and its intrabrain distribution were faster than metabolite systemic disposition, both with respect to its formation and subsequent elimination. Parenthetically, in humans, given that hydroxybupropion and bupropion have a similar half-life after bupropion administration (Sweet et al., 1995; Hsyu et al., 1997), it is possible that hydroxybupropion disposition, at least in plasma, is also rate-limited by bupropion. In our rat study, comparing systemic AUCs of formed metabolite to bupropion and correcting for differences in clearance between bupropion and that of the preformed metabolite (Rowland and Tozer, 2011), the fraction of bupropion metabolized to hydroxybupropion was 1.1%. In the compartmental model, the ratio of formation clearance to total clearance of bupropion was 0.4%. The difference is attributed to a small presystemic clearance component prior to bupropion systemic absorption. Albeit small, this first-pass effect is surprising given that bupropion was administered subcutaneously. In response to nonconvergence of the combined formed and preformed metabolite plasma model that did not include this first-pass effect, alternative explanations were investigated: 1) bupropion-mediated alteration of formed metabolite disposition (altered clearance or VD) or 2) different bioavailability for the two dose groups. These alternative structures were found unable to generate a model that included the two dose groups. In addition, the possibilities that hydroxybupropion probe recovery was enhanced in the presence of bupropion or of bias in the analysis of the metabolite in the presence of bupropion were considered and discounted. At this point, the cause of the presumed presystemic component is not understood.

The observation that bupropion brain kinetics paralleled those in plasma indicates that, like hydroxybupropion, bupropion disposition in brain was faster than its overall (systemic) disposition in the rat. In fact, brain equilibration half-life for each compound (based on the equation t1/2,equil = Vb ⋅ ln2/CLout; Liu et al., 2005) was only 1.4 minutes and 4.6 minutes for bupropion and hydroxybuprion, respectively. As shown in Fig. 1, in four of the five animals receiving bupropion, there was a distinct peak in Kp,uu for bupropion occurring by the second collection interval. A significant improvement in model performance (AIC and goodness-of-fit plots) was achieved by incorporating a time dependency in CLin,B, with this decreasing over time. In the final population model, the ratio of CLin/CLout was 1.9 and 1.7 (relative standard error of the estimate = 5.6% and 6.1%) for bupropion and hydroxybupropion, respectively, both in good agreement with the AUC ratio estimates in Table 1. The model did not include brain ECF bulk flow, since the estimated value of 0.18 to 0.29 µl/min ⋅ g brain (Szentistványi et al., 1984) is well below 1% of the CLout estimates and thus is a negligible contributing factor to brain clearance. The utility of modeling plasma and brain distribution across the BBB is that this approach converts an observation (Kp,uu) into parameters (CLin and CLout) that correlate with physiologic carrier-mediated processes that are potentially scalable between species (Qiu et al., 2014), and whose function could be sensitive to intersubject variability caused by disease or genetic variability as well as drug–drug and drug–metabolite interactions.

The experimentally obtained pKa of bupropion has been estimated at 7.9 (Gondaliya and Pundarikakshudu, 2003) and 8.6 (Fridén et al., 2011). Taking the average of these two values, and assuming that brain ECF is 0.1 log unit more acidic than plasma (pH 7.3 versus pH 7.4; Fridén et al., 2011), results in a predicted diffusional equilibrium preference on the brain side of 1.01, which supports that the CLin/CLout ratios of approximately 2 are due to an uptake transporter for bupropion and hydroxybupropion at the BBB. The net uptake asymmetry observed is similar to oxycodone BBB transport in rats, (Boström et al., 2006), which showed a net 3-fold asymmetry favoring rat brain ECF relative to unbound plasma concentrations. Subsequent in vitro studies with oxycodone (Okura et al., 2008)—as well as more recent in vitro transport or in situ brain perfusion studies with several other low molecular weight weakly basic drugs, such as apomorphine (Okura et al., 2014), clonidine (André et al., 2009), codeine (Fischer et al., 2010), diphenhydramine (Shimomura et al., 2013), and nicotine (Cisternino et al., 2013)—implicate a pH-dependent proton-coupled antiporter at the BBB (Gharavi et al., 2015). It is possible that this transporter may also apply to bupropion and hydroxybupropion. Moreover, the proton-coupled antiporter has been suggested to be capable of bidirectional transport (Cisternino et al., 2013). It is possible that the overshoot in bupropion Kp,uu, which was modeled as a time-dependent distributional clearance, may have been due to eventual replacement of protons by bupropion and/or hydroxybupropion on the abluminal side. This may have resulted in a decrease in CLin over time due to reduced function, or just to loss of the proton gradient over time, much like occurs with proton-coupled dipeptide transport in the small intestine (Ganapathy and Leibach, 1983). Interestingly, a similar time-dependent Kp,uu was observed with oxycodone (Boström et al., 2006). It is possible that the overshoot observed with bupropion is due to an experimental artifact (namely, a decline in probe recovery of bupropion after administration and lasting for 2 to 3 hours, at which point it reached a constant value). As is standard practice in microdialysis research, probes in this study were inserted 24 hours before an experiment and perfused for 2 hours prior to drug administration to reduce the possibility for such an artifact. At a minimum, our observations point to additional studies to develop a better mechanistic understanding of bupropion and hydroxybupropion transport across the BBB.

Bupropion’s effects in rodent models of depression have been linked to its ability to increase dopamine and norepinephrine concentrations in brain ECF, as determined using microdialysis sampling (Nomikos et al., 1989, 1992). More recently, Li et al. (2002) evaluated the effect of a 10-mg/kg bupropion subcutaneous dose on dopamine and norepinephrine levels in the ECF of medial prefrontal cortex of rats, thus employing the same dose, route, and microdialysis probe placement as used in our study. In the study by Li et al. (2002), the increase in dopamine peaked at 262% over baseline 90 minutes after administration. A dopamine increase at that time is in accord with the median peak bupropion concentration of 504 nM observed during the 60- to 90-minute collection interval (Fig. 5), and its proximity to its reported IC50 at DAT of 550–660 nM (Damaj et al., 2004; Lukas et al., 2010). Although hydroxybupropion also possesses inhibitory activity at DAT in the same range (790 nM) in rats, its contribution to increasing extracellular dopamine would be expected to be minimal, given the median concentration of 22 nM observed. By contrast, hydroxybupropion exposure in plasma in humans is approximately an order of magnitude greater than bupropion (Johnston et al., 2001; Learned-Coughlin et al., 2003; Benowitz et al., 2013). Translation of the rat bupropion and hydroxybupropion plasma-brain distributional clearances to humans suggests that monoamine contributions to bupropion’s antidepressant effects via monoamine reuptake inhibition are due to hydroxybupropion. Median hydroxybupropion brain ECF concentrations are similar to its DAT IC50 and are approximately 3-fold above its NET IC50 (Fig. 6), whereas peak bupropion brain ECF concentrations are approximately 7-fold below the DAT IC50 and are even more so relative to that for NET. Importantly, our predictions of the much larger exposure to the metabolite in brain ECF agree with its reported 7-fold higher concentrations than bupropion in human CSF (Cooper, et al., 1994). Receptor occupancy studies using PET (Meyer et al., 2002; Learned-Coughlin et al., 2003) or SPECT (Argyelán et al., 2005) tracers specific for DAT, and after attainment of steady-state kinetics based on several days of dosing 150 mg of the SR formulation twice daily, indicate modest occupancy of around 20% in both patients with and without depression. In one of these studies (Learned-Coughlin et al., 2003), DAT occupancy was sustained for at least 24 hours. Our predicted sustained exposure to hydroxybupropion (Fig. 6) agrees with the reported sustained occupancy at this transporter and suggests that it was due to the metabolite. However, the low occupancy reported in these studies is below that which our predictions would suggest (approximately 50%) based on the simulated concentrations being similar to the reported IC50 for hydroxybupropion at this transporter (630 nM; Lukas et al., 2010). This difference identifies the need for studies to investigate the mechanism of bupropion and hydroxybupropion transport across blood–brain surrogate models and, if a transporter is involved, to apply mass spectrometry–based proteomics to support interspecies scaling (Qiu et al., 2014). The predicted exposures for bupropion and hydroxybupropion, together with their IC50 values for NET, indicate that, if norepinephrine levels are increased in humans via NET inhibition, this would largely be attributed to hydroxybupropion, and not bupropion.

In conclusion, a pharmacokinetic model that predicts bupropion and hydroxybupropion concentrations in brain ECF of rats has been developed. The model asserts a carrier-mediated mechanism contributes to the plasma to brain transfer of both compounds. Similar to what has been done with atomoxetine and duloxetine (Kielbasa and Stratford, 2012) and clozapine and its active metabolite, N-desmethylclozapine (Li et al., 2014), to translate rat BBB kinetics to humans to predict human brain exposure, our approach predicts that the dopamine transporter occupancy observed in humans using PET and SPECT is due to hydroxybupropion and that the metabolite is responsible for a direct effect on increasing synaptic dopamine and norepinephrine via DAT and NET inhibition, respectively.

Acknowledgments

The authors thank Robert Bies (University at Buffalo, State University of New York) and Serge Guzy (POP-PHARM) for collegial support during the modeling analysis portion of this work. Erin Gorse is also thankfully acknowledged for support with table and figure preparation.

Authorship Contributions

Participated in research design: Cremers, Flik, Rollema, Stratford.

Conducted experiments: Flik, Folgering.

Performed data analysis: Stratford.

Wrote or contributed to the writing of the manuscript: Cremers, Flik, Folgering, Rollema, Stratford.

Footnotes

Abbreviations

−2LL
−2 × log likelihood
AIC
Akaike information criterion
AUC
area under the curve
BAV
between-animal variability
BBB
blood–brain barrier
CL
clearance
DAT
dopamine reuptake transporter
ECF
extracellular fluid
HPLC
high-performance liquid chromatography
Kp,uu
concentration ratios of brain ECF to plasma
MS/MS
tandem mass spectrometry
NET
norepinephrine reuptake transporter
OFV
objective function value
PD
pharmacodynamics
PET
positron emission tomography
PK
pharmacokinetics
SPECT
single photon emission computed tomography
SR
extended-release
Vb
brain distribution volume

References

  1. ↵
    1. André P,
    2. Debray M,
    3. Scherrmann JM, and
    4. Cisternino S
    (2009) Clonidine transport at the mouse blood-brain barrier by a new H+ antiporter that interacts with addictive drugs. J Cereb Blood Flow Metab 29:1293–1304.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Argyelán M,
    2. Szabó Z,
    3. Kanyó B,
    4. Tanács A,
    5. Kovács Z,
    6. Janka Z, and
    7. Pávics L
    (2005) Dopamine transporter availability in medication free and in bupropion treated depression: a 99mTc-TRODAT-1 SPECT study. J Affect Disord 89:115–123.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Ascher JA,
    2. Cole JO,
    3. Colin JN,
    4. Feighner JP,
    5. Ferris RM,
    6. Fibiger HC,
    7. Golden RN,
    8. Martin P,
    9. Potter WZ,
    10. Richelson E,
    11. et al.
    (1995) Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 56:395–401.
    OpenUrlPubMed
  4. ↵
    1. Bondarev ML,
    2. Bondareva TS,
    3. Young R, and
    4. Glennon RA
    (2003) Behavioral and biochemical investigations of bupropion metabolites. Eur J Pharmacol 474:85–93.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Benowitz NL,
    2. Zhu AZ,
    3. Tyndale RF,
    4. Dempsey D, and
    5. Jacob P
    (2013) Influence of CYP2B6 genetic variants on plasma and urine concentrations of bupropion and metabolites at steady state. Pharmacogent Genomics 23:135–141.
    OpenUrlCrossRef
  6. ↵
    1. Boström E,
    2. Simonsson USH, and
    3. Hammarlund-Udenaes M
    (2006) In vivo blood-brain barrier transport of oxycodone in the rat: indications for active influx and implications for pharmacokinetics/pharmacodynamics. Drug Metab Dispos 34:1624–1631.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Cisternino S,
    2. Chapy H,
    3. André P,
    4. Smirnova M,
    5. Debray M, and
    6. Scherrmann JM
    (2013) Coexistence of passive and proton antiporter-mediated processes in nicotine transport at the mouse blood-brain barrier. AAPS J 15:299–307.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Cooper BR,
    2. Wang CM,
    3. Cox RF,
    4. Norton R,
    5. Shea V, and
    6. Ferris RM
    (1994) Evidence that the acute behavioral and electrophysiological effects of bupropion (Wellbutrin) are mediated by a noradrenergic mechanism. Neuropsychopharmacology 11:133–141.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Cremers TIFH,
    2. de Vries MG,
    3. Huinink KD,
    4. van Loon JP,
    5. v d Hart M,
    6. Ebert B,
    7. Westerink BH, and
    8. De Lange EC
    (2009) Quantitative microdialysis using modified ultraslow microdialysis: direct rapid and reliable determination of free brain concentrations with the MetaQuant technique. J Neurosci Methods 178:249–254.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Damaj MI,
    2. Carroll FI,
    3. Eaton JB,
    4. Navarro HA,
    5. Blough BE,
    6. Mirza S,
    7. Lukas RJ, and
    8. Martin BR
    (2004) Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors. Mol Pharmacol 66:675–682.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Davies B and
    2. Morris T
    (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10:1093–1095.
    OpenUrlCrossRefPubMed
  12. ↵
    1. de Lange ECM
    (2013) The mastermind approach to CNS drug therapy: translational prediction of human brain distribution, target site kinetics, and therapeutic effects. Fluids Barriers CNS 10:12.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Dong J and
    2. Blier P
    (2001) Modification of norepinephrine and serotonin, but not dopamine, neuron firing by sustained bupropion treatment. Psychopharmacology (Berl) 155:52–57.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Fava M,
    2. Rush AJ,
    3. Thase ME,
    4. Clayton A,
    5. Stahl SM,
    6. Pradko JF, and
    7. Johnston JA
    (2005) 15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL. Prim Care Companion J Clin Psychiatry 7:106–113.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Fischer W,
    2. Bernhagen J,
    3. Neubert RHH, and
    4. Brandsch M
    (2010) Uptake of codeine into intestinal epithelial (Caco-2) and brain endothelial (RBE4) cells. Eur J Pharm Sci 41:31–42.
    OpenUrlCrossRefPubMed
  16. ↵
    1. Fridén M,
    2. Bergström F,
    3. Wan H,
    4. Rehngren M,
    5. Ahlin G,
    6. Hammarlund-Udenaes M, and
    7. Bredberg U
    (2011) Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods. Drug Metab Dispos 39:353–362.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    1. Ganapathy V and
    2. Leibach FH
    (1983) Role of pH gradient and membrane potential in dipeptide transport in intestinal and renal brush-border membrane vesicles from the rabbit. Studies with L-carnosine and glycyl-L-proline. J Biol Chem 258:14189–14192.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Gharavi R,
    2. Hedrich W,
    3. Wang H, and
    4. Hassan HE
    (2015) Transporter-mediated disposition of opioids: implications for clinical drug interactions. Pharm Res 32:2477–2502.
    OpenUrlPubMed
  19. ↵
    1. Gondaliya D and
    2. Pundarikakshudu K
    (2003) Studies in formulation and pharmacotechnical evaluation of controlled release transdermal delivery system of bupropion. AAPS PharmSciTech 4:E3.
    OpenUrlPubMed
  20. ↵
    1. Hsyu PH,
    2. Singh A,
    3. Giargiari TD,
    4. Dunn JA,
    5. Ascher JA, and
    6. Johnston JA
    (1997) Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus nonsmokers. J Clin Pharmacol 37:737–743.
    OpenUrlCrossRefPubMed
  21. ↵
    1. Jefferson JW,
    2. Pradko JF, and
    3. Muir KT
    (2005) Bupropion for major depressive disorder: pharmacokinetic and formulation considerations. Clin Ther 27:1685–1695.
    OpenUrlCrossRefPubMed
  22. ↵
    1. Johnson M,
    2. Kozielska M,
    3. Pilla Reddy V,
    4. Vermeulen A,
    5. Li C,
    6. Grimwood S,
    7. de Greef R,
    8. Groothuis GMM,
    9. Danhof M, and
    10. Proost JH
    (2011) Mechanism-based pharmacokinetic-pharmacodynamic modeling of the dopamine D2 receptor occupancy of olanzapine in rats. Pharm Res 28:2490–2504.
    OpenUrlCrossRefPubMed
  23. ↵
    1. Johnston AJ,
    2. Ascher J,
    3. Leadbetter R,
    4. Schmith VD,
    5. Patel DK,
    6. Durcan M, and
    7. Bentley B
    (2002) Pharmacokinetic optimisation of sustained-release bupropion for smoking cessation. Drugs 62 (Suppl 2):11–24.
    OpenUrl
  24. ↵
    1. Johnston JA,
    2. Fiedler-Kelly J,
    3. Glover ED,
    4. Sachs DPL,
    5. Grasela TH, and
    6. DeVeaugh-Geiss J
    (2001) Relationship between drug exposure and the efficacy and safety of bupropion sustained release for smoking cessation. Nicotine Tob Res 3:131–140.
    OpenUrlAbstract
  25. ↵
    1. Kielbasa W and
    2. Stratford RE Jr.
    (2012) Exploratory translational modeling approach in drug development to predict human brain pharmacokinetics and pharmacologically relevant clinical doses. Drug Metab Dispos 40:877–883.
    OpenUrlAbstract/FREE Full Text
  26. ↵
    1. Kozielska M,
    2. Johnson M,
    3. Pilla Reddy V,
    4. Vermeulen A,
    5. Li C,
    6. Grimwood S,
    7. de Greef R,
    8. Groothuis GMM,
    9. Danhof M, and
    10. Proost JH
    (2012) Pharmacokinetic-pharmacodynamic modeling of the D₂ and 5-HT (2A) receptor occupancy of risperidone and paliperidone in rats. Pharm Res 29:1932–1948.
    OpenUrlCrossRefPubMed
  27. ↵
    1. Learned-Coughlin SM,
    2. Bergström M,
    3. Savitcheva I,
    4. Ascher J,
    5. Schmith VD, and
    6. Långstrom B
    (2003) In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography. Biol Psychiatry 54:800–805.
    OpenUrlCrossRefPubMed
  28. ↵
    1. Li CH,
    2. Stratford RE Jr.,
    3. Velez de Mendizabal N,
    4. Cremers TIFH,
    5. Pollock BG,
    6. Mulsant BH,
    7. Remington G, and
    8. Bies RR
    (2014) Prediction of brain clozapine and norclozapine concentrations in humans from a scaled pharmacokinetic model for rat brain and plasma pharmacokinetics. J Transl Med 12:203.
    OpenUrlCrossRefPubMed
  29. ↵
    1. Li SXM,
    2. Perry KW, and
    3. Wong DT
    (2002) Influence of fluoxetine on the ability of bupropion to modulate extracellular dopamine and norepinephrine concentrations in three mesocorticolimbic areas of rats. Neuropharmacology 42:181–190.
    OpenUrlCrossRefPubMed
  30. ↵
    1. Liu X,
    2. Smith BJ,
    3. Chen C,
    4. Callegari E,
    5. Becker SL,
    6. Chen X,
    7. Cianfrogna J,
    8. Doran AC,
    9. Doran SD,
    10. Gibbs JP,
    11. et al.
    (2005) Use of a physiologically based pharmacokinetic model to study the time to reach brain equilibrium: an experimental analysis of the role of blood-brain barrier permeability, plasma protein binding, and brain tissue binding. J Pharmacol Exp Ther 313:1254–1262.
    OpenUrlAbstract/FREE Full Text
  31. ↵
    1. Lukas RJ,
    2. Muresan AZ,
    3. Damaj MI,
    4. Blough BE,
    5. Huang X,
    6. Navarro HA,
    7. Mascarella SW,
    8. Eaton JB,
    9. Marxer-Miller SK, and
    10. Carroll FI
    (2010) Synthesis and characterization of in vitro and in vivo profiles of hydroxybupropion analogues: aids to smoking cessation. J Med Chem 53:4731–4748.
    OpenUrlCrossRefPubMed
  32. ↵
    1. Meyer JH,
    2. Goulding VS,
    3. Wilson AA,
    4. Hussey D,
    5. Christensen BK, and
    6. Houle S
    (2002) Bupropion occupancy of the dopamine transporter is low during clinical treatment. Psychopharmacology (Berl) 163:102–105.
    OpenUrlCrossRefPubMed
  33. ↵
    1. Nomikos GG,
    2. Damsma G,
    3. Wenkstern D, and
    4. Fibiger HC
    (1989) Acute effects of bupropion on extracellular dopamine concentrations in rat striatum and nucleus accumbens studied by in vivo microdialysis. Neuropsychopharmacology 2:273–279.
    OpenUrlCrossRefPubMed
  34. ↵
    1. Nomikos GG,
    2. Damsma G,
    3. Wenkstern D, and
    4. Fibiger HC
    (1992) Effects of chronic bupropion on interstitial concentrations of dopamine in rat nucleus accumbens and striatum. Neuropsychopharmacology 7:7–14.
    OpenUrlPubMed
  35. ↵
    1. Okura T,
    2. Hattori A,
    3. Takano Y,
    4. Sato T,
    5. Hammarlund-Udenaes M,
    6. Terasaki T, and
    7. Deguchi Y
    (2008) Involvement of the pyrilamine transporter, a putative organic cation transporter, in blood-brain barrier transport of oxycodone. Drug Metab Dispos 36:2005–2013.
    OpenUrlAbstract/FREE Full Text
  36. ↵
    1. Okura T,
    2. Higuchi K,
    3. Kitamura A, and
    4. Deguchi Y
    (2014) Proton-coupled organic cation antiporter-mediated uptake of apomorphine enantiomers in human brain capillary endothelial cell line hCMEC/D3. Biol Pharm Bull 37:286–291.
    OpenUrlCrossRefPubMed
  37. ↵
    1. Pang KS and
    2. Gillette JR
    (1979) Sequential first-pass elimination of a metabolite derived from a precursor. J Pharmacokinet Biopharm 7:275–290.
    OpenUrlCrossRefPubMed
  38. ↵
    1. Qiu X,
    2. Zhang H, and
    3. Lai Y
    (2014) Quantitative targeted proteomics for membrane transporter proteins: method and application. AAPS J 16:714–726.
    OpenUrlCrossRefPubMed
  39. ↵
    1. Rowland M and
    2. Tozer TN
    (2011) Clinical Pharmacokinetics and Pharmacodynamics Concepts and Applications, 4th ed, Walters Kluwer, Lippincott Williams and Wilkins, Philadelphia.
  40. ↵
    1. Sharma V and
    2. McNeill JH
    (2009) To scale or not to scale: the principles of dose extrapolation. Br J Pharmacol 157:907–921.
    OpenUrlCrossRefPubMed
  41. ↵
    1. Shimomura K,
    2. Okura T,
    3. Kato S,
    4. Couraud P-O,
    5. Schermann JM,
    6. Terasaki T, and
    7. Deguchi Y
    (2013) Functional expression of a proton-coupled organic cation (H+/OC) antiporter in human brain capillary endothelial cell line hCMEC/D3, a human blood-brain barrier model. Fluids Barriers CNS 10:8.
    OpenUrlCrossRefPubMed
  42. ↵
    1. Slemmer JE,
    2. Martin BR, and
    3. Damaj MI
    (2000) Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther 295:321–327.
    OpenUrlAbstract/FREE Full Text
  43. ↵
    1. Spreafico M and
    2. Jacobson MP
    (2013) In silico prediction of brain exposure: drug free fraction, unbound brain to plasma concentration ratio and equilibrium half-life. Curr Top Med Chem 13:813–820.
    OpenUrlCrossRefPubMed
  44. ↵
    1. Suckow RF,
    2. Smith TM,
    3. Perumal AS, and
    4. Cooper TB
    (1986) Pharmacokinetics of bupropion and metabolites in plasma and brain of rats, mice, and guinea pigs. Drug Metab Dispos 14:692–697.
    OpenUrlAbstract
  45. ↵
    1. Sweet RA,
    2. Pollock BG,
    3. Kirshner M,
    4. Wright B,
    5. Altieri LP, and
    6. DeVane CL
    (1995) Pharmacokinetics of single- and multiple-dose bupropion in elderly patients with depression. J Clin Pharmacol 35:876–884.
    OpenUrlCrossRefPubMed
  46. ↵
    1. Szentistványi I,
    2. Patlak CS,
    3. Ellis RA, and
    4. Cserr HF
    (1984) Drainage of interstitial fluid from different regions of rat brain. Am J Physiol 246:F835–F844.
    OpenUrl
  47. ↵
    1. Velez de Mendizabal N,
    2. Jackson K,
    3. Eastwood B,
    4. Swanson S,
    5. Bender DM,
    6. Lowe S, and
    7. Bies RR
    (2015) A population PK model for citalopram and its major metabolite, N-desmethyl citalopram, in rats. J Pharmacokinet Pharmacodyn 42:721–733.
    OpenUrlCrossRefPubMed
  48. ↵
    1. Wooltorton E
    (2002) Bupropion (Zyban, Wellbutrin SR): reports of deaths, seizures, serum sickness. CMAJ 166:68.
    OpenUrlFREE Full Text
  49. ↵
    1. Yeniceli D,
    2. Şener E,
    3. Korkmaz OT,
    4. Doğrukol-Ak D, and
    5. Tuncel N
    (2011) A simple and sensitive LC-ESI-MS (ion trap) method for the determination of bupropion and its major metabolite, hydroxybupropion in rat plasma and brain microdialysates. Talanta 84:19–26.
    OpenUrlCrossRefPubMed
Back to top

In this issue

Download PDF
Article Alerts
Email Article
Citation Tools
Research ArticleArticle

Bupropion and Hydroxybupropion Brain Pharmacokinetics

Thomas I.F.H. Cremers, Gunnar Flik, Joost H.A. Folgering, Hans Rollema and Robert E. Stratford
Drug Metabolism and Disposition May 1, 2016, 44 (5) 624-633; DOI: https://doi.org/10.1124/dmd.115.068932
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Jump to section

Advertisement